tracken
Bristol-Myers Squibb Aktie News
Neutral
Seeking Alpha
●
etwa 4 Stunden alt
Bristol-Myers Squibb Company (NYSE:BMY ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Chuck Triano - SVP and Head of IR Chris Boerner - Board Chair and CEO David Elkins - CFO Adam Lenkowsky - CCO Samit Hirawat - CMO and Head of Global Drug Development Conference Call Participants Chris Schott - JPMorgan Mohit Bansal - Wells Fargo Luisa Hector - Berenberg Geoff...
Positiv
Seeking Alpha
●
etwa 4 Stunden alt
Bristol-Myers Squibb Company is undervalued, trading 30% below its intrinsic value, with a low price-to-free-cash-flow ratio indicating a strong buying opportunity. In the first quarter, Bristol-Myers Squibb did beat expectations for revenue and earnings per share, but had to report declining sales. Management expects a revenue decline in 2025 due to legacy portfolio drops, but growth portfolio...
Negativ
Seeking Alpha
●
etwa 4 Stunden alt
Bristol-Myers Squibb Company's Q1 2025 earnings show a 6% YoY revenue decline but improved EPS, with upgraded full-year guidance and a strong dividend yield of over 5%. BMY's growth portfolio is nearing 50% of revenues, but legacy assets and unmet peak revenue forecasts for new drugs raise concerns. Cobenfy's recent trial failure and underperformance of key assets like Sotyktu and Abecma contri...
Neutral
Investors Business Daily
●
etwa 5 Stunden alt
Bristol Myers Squibb stock dropped Thursday, though the drugmaker beat first-quarter expectations and raised its outlook for the year.
Positiv
Barrons
●
etwa 8 Stunden alt
Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.
Positiv
Reuters
●
etwa 9 Stunden alt
Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's own immune system to fight cancer.
Positiv
CNBC
●
etwa 9 Stunden alt
Bristol Myers Squibb beat first-quarter estimates and hiked its revenue and profit guidance for the year, as the drugmaker cuts costs. The company said its guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not President Donald Trump's planned duties on pharmaceuticals imported into the U.S.
Neutral
Business Wire
●
etwa 9 Stunden alt
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports First Quarter Financial Results for 2025.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
